Novel strategy for selection of monoclonal antibodies against highly conserved antigens: phage library panning against ephrin-B2 displayed on yeast.

TitleNovel strategy for selection of monoclonal antibodies against highly conserved antigens: phage library panning against ephrin-B2 displayed on yeast.
Publication TypeJournal Article
Year of Publication2012
AuthorsGu X, Vedvyas Y, Chen X, Kaushik T, Hwang C-I, Hu X, Nikitin AY, Jin MM
JournalPLoS One
Volume7
Issue1
Paginatione30680
Date Published2012
ISSN1932-6203
KeywordsAmino Acid Sequence, Animals, Antibodies, Monoclonal, Antigens, Cells, Cultured, CHO Cells, Conserved Sequence, Cricetinae, Cricetulus, Ephrin-B2, HCT116 Cells, HEK293 Cells, High-Throughput Screening Assays, Humans, Mice, Mice, Nude, Models, Biological, Molecular Sequence Data, Peptide Library, Protein Binding, Receptor, EphB4, Sequence Homology, Amino Acid, Xenograft Model Antitumor Assays, Yeasts
Abstract

Ephrin-B2 is predominately expressed in endothelium of arterial origin, involved in developmental angiogenesis and neovasculature formation through its interaction with EphB4. Despite its importance in physiology and pathological conditions, it has been challenging to produce monoclonal antibodies against ephrin-B2 due to its high conservation in sequence throughout human and rodents. Using a novel approach for antibody selection by panning a phage library of human antibody against antigens displayed in yeast, we have isolated high affinity antibodies against ephrin-B2. The function of one high affinity binder (named as 'EC8') was manifested in its ability to inhibit ephrin-B2 interaction with EphB4, to cross-react with murine ephrin-B2, and to induce internalization into ephrin-B2 expressing cells. EC8 was also compatible with immunoprecipitation and detection of ephrin-B2 expression in the tissue after standard chemical fixation procedure. Consistent with previous reports on ephrin-B2 induction in some epithelial tumors and tumor-associated vasculatures, EC8 specifically detected ephrin-B2 in tumors as well as the vasculature within and outside of the tumors. We envision that monoclonal antibody developed in this study may be used as a reagent to probe ephrin-B2 distribution in normal as well as in pathological conditions and to antagonize ephrin-B2 interaction with EphB4 for basic science and therapeutic applications.

DOI10.1371/journal.pone.0030680
Alternate JournalPLoS One
PubMed ID22292016
PubMed Central IDPMC3264634
Grant ListU54-AI057158 / AI / NIAID NIH HHS / United States
GM090320 / GM / NIGMS NIH HHS / United States
R56 CA096823 / CA / NCI NIH HHS / United States
CA112354 / CA / NCI NIH HHS / United States
R01 CA096823 / CA / NCI NIH HHS / United States
CA96823 / CA / NCI NIH HHS / United States
U54 AI057158 / AI / NIAID NIH HHS / United States
R01 CA112354 / CA / NCI NIH HHS / United States
AI179532 / AI / NIAID NIH HHS / United States
R01 GM090320 / GM / NIGMS NIH HHS / United States
Related Institute: 
Molecular Imaging Innovations Institute (MI3)

Weill Cornell Medicine
Department of Radiology
525 East 68th Street New York, NY 10065